Stem Cell Manufacturing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented by Product (Consumables, Instruments, Stem Cell Lines), By Application (Research Applications, Clinical Application, Cell and Tissue Banking Applications), By End User (Pharmaceutical and Biotechnology Companies, Academic Institutes, Research Laboratories and Contract Research Organizations, Hospitals and Surgical Centers, Cell and Tissue banks, Others), By Region, By Competition

Market Overview

Global Stem Cell Manufacturing Market has valued at USD 11.25 billion in 2022 and is anticipated to project robust growth in the forecast period with a CAGR of 12.64% through 2028. A stem cell is an unspecialized cell that develops into specialized cell that makes up different types of tissue in the human body. They are characterized by the ability to renew themselves through mitotic cell division and differentiating into a diverse range of specialized cell types. They are vital to the development, growth, maintenance, and repair of brains, bones, muscles, nerves, blood, skin, and other organs. Stem cells are found in every human, from the early stages of development to the end of life. Stem cell research holds tremendous promise for the development of novel therapies for many serious diseases and injuries. Stem cell-based treatments have been established as a clinical standard of care for some conditions, such as hematopoietic stem cell transplants for leukemia and epithelial stem cell-based treatments for burns and corneal disorders. The scope of potential stem cell-based therapies has expanded in recent years due to advances in stem cell research. People who might benefit from stem cell therapies include those with spinal cord injuries, type 1 diabetes, Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease, heart disease, stroke, burns, cancer, and osteoarthritis.In the future, they may be used to replace cells and tissues that have been damaged or lost due to any disease. For instance, in September 2021, STEMCELL Technologies launched human pluripotent stem cell (hPSC) characterization and banking services in partnership with WiCell. These services, offered through STEMCELL’s Contract Assay Services division, provide researchers with comprehensive cell quality assessments and enable them to generate cell banks using standardized practices.

Key Market Drivers

Increasing Prevalence of Chronic Diseases

Chronic diseases such as diabetes, heart disease, neurodegenerative disorders, and autoimmune diseases often result in irreversible tissue damage or organ dysfunction. Stem cell-based regenerative therapies offer the potential to repair or replace damaged tissues, offering hope for patients who have limited treatment options. As the prevalence of chronic diseases rises, so does the demand for stem cell therapies, driving the growth of the stem cell manufacturing market. With a growing number of individuals affected by chronic diseases, the patient pool for stem cell therapies expands significantly. This larger potential customer base provides a substantial market for stem cell-based products and treatments. Many chronic diseases are considered incurable using traditional medical approaches. Stem cell therapies hold the promise of treating these conditions by harnessing the regenerative capabilities of stem cells. Patients with chronic diseases are often willing to explore innovative treatments, which further fuels the demand for stem cell-based solutions. The increasing prevalence of chronic diseases has led to a surge in clinical trials and research focused on developing stem cell therapies for these conditions. This heightened research activity attracts investment and funding, fostering innovation and the development of new stem cell manufacturing technologies and products. Regulatory agencies have recognized the potential of stem cell therapies to address unmet medical needs in chronic disease management. They have created more favorable regulatory pathways for stem cell-based products and treatments, facilitating their development and commercialization. Pharmaceutical companies, recognizing the market potential of stem cell therapies for chronic diseases, have increasingly entered the field through partnerships, acquisitions, and in-house development efforts. This industry engagement has injected significant capital into stem cell manufacturing, accelerating its growth. As patients and their families become more informed about stem cell-based treatments and their potential benefits, they actively seek out these options for managing chronic diseases. Patient advocacy and awareness groups also play a role in promoting stem cell therapies.

Rising Investment and Collaboration

Increased investment in stem cell research and manufacturing allows for more extensive and in-depth R&D activities. This, in turn, leads to the development of innovative manufacturing technologies, improved quality control, and the discovery of new applications for stem cells. Collaborative efforts between research institutions, universities, and biotech companies can pool expertise and resources, expediting the development of new therapies and products. Investment is crucial for scaling up stem cell manufacturing processes from laboratory-scale to industrial-scale production. The infusion of capital enables the establishment of advanced manufacturing facilities, automation of production processes, and optimization of bioprocessing techniques. This results in increased production efficiency and lower costs, making stem cell-based therapies more accessible and affordable. Collaboration between pharmaceutical companies, research institutions, and regulatory bodies facilitates the design and execution of clinical trials for stem cell-based therapies. These trials are essential for demonstrating safety and efficacy, a prerequisite for regulatory approvals. Investment supports the costly clinical trial process, increasing the likelihood of successful outcomes and product commercialization. Collaboration often involves partnerships between pharmaceutical companies and stem cell manufacturers, leading to the commercialization of stem cell-based therapies. These partnerships provide access to established distribution networks and marketing expertise, enabling the rapid entry of stem cell products into the market. This, in turn, promotes market growth. Collaborative efforts foster the exchange of knowledge, best practices, and technical know-how among industry stakeholders. This knowledge sharing accelerates the standardization of manufacturing processes and quality control measures, ensuring consistent product quality and safety. Collaboration and investment allow for the exploration of diverse applications for stem cells, including not only regenerative medicine but also drug discovery, disease modeling, and toxicology testing. This diversification broadens the market by creating opportunities beyond therapeutic applications. For instance, as per the article published in September 2022 in PubMed, stem cell therapy involving in vitro and in vivo studies is shown to be safe and efficacious in treating various diseases. As per the same source, stem cell treatment seeks to restore or repair damaged organs and congenital malformations using human stem cells such as embryonic stem cells (ESCs), adult stem cells (ASCs), and induced pluripotent stem cells (iPSCs).

Patient Awareness and Demand

As patients become more aware of stem cell-based therapies and their potential benefits, the market size for these treatments expands. Patients suffering from a wide range of medical conditions, including chronic diseases, injuries, and degenerative disorders, actively seek out information and options for stem cell-based treatments. Patients and their families are increasingly proactive in managing their healthcare. They research treatment options, attend medical conferences, and engage with healthcare providers to explore stem cell therapies. This demand-driven approach has led to a surge in inquiries and requests for stem cell treatments. Patient advocacy groups and disease-specific organizations often raise awareness about stem cell therapies as potential solutions for various medical conditions. These campaigns not only educate patients but also encourage them to consider stem cell treatments as viable alternatives. Positive outcomes and testimonials from patients who have experienced successful stem cell treatments have a significant impact on driving demand. Patients who achieve improved quality of life or recovery from debilitating conditions often share their experiences, inspiring others to explore stem cell therapies. Patient demand for stem cell treatments extends beyond borders. Some patients are willing to travel to countries or regions where stem cell therapies are available, even if they are not accessible in their home countries. This trend has created a global market for stem cell manufacturing, with patients seeking treatment options internationally. Patient demand for safe and regulated stem cell therapies has encouraged regulatory bodies to establish clear guidelines and ethical standards for the industry. This, in turn, enhances patient confidence and drives further demand. For instance, in September 2021, STEMCELL Technologies launched human pluripotent stem cell (hPSC) characterization and banking services in partnership with WiCell, making it easier for pluripotent stem cell researchers to achieve critical yet often overlooked steps.

Download Free Sample Report

Key Market Challenges

Regulatory Complexities

Navigating the regulatory pathways for stem cell manufacturing can be a lengthy and expensive process. Companies must invest substantial resources in regulatory compliance, including conducting preclinical and clinical trials, compiling extensive documentation, and engaging in ongoing communication with regulatory agencies. This can delay market entry and increase the cost of developing and commercializing stem cell products. Stem cell regulations can vary significantly from one country or region to another. These inconsistencies can create barriers for companies looking to expand their products globally, as they must adapt to different regulatory requirements in each market. Harmonizing regulations across regions can be challenging and time-consuming. Some stem cell sources, such as embryonic stem cells, are subject to ethical debates and legal restrictions in certain regions. This can limit the types of research and manufacturing activities that companies can engage in, hindering the development of specific stem cell therapies. Regulatory complexities can introduce uncertainty for investors in the stem cell manufacturing sector. The lengthy and uncertain regulatory approval process may discourage potential investors from providing the necessary capital for research and development or scaling up production. Meeting regulatory requirements often involves implementing robust quality control systems, conducting rigorous testing, and adhering to strict manufacturing standards. These compliance costs can be substantial and may pose a barrier for smaller companies or startups entering the market. Stem cell therapies are held to high safety and efficacy standards due to their potential risks and benefits. Meeting these demands requires extensive research and clinical testing, which can extend the development timeline and increase costs.

Quality Control and Standardization

Stem cell therapies and products must meet rigorous quality standards to ensure safety and efficacy. Variability in manufacturing processes and lack of standardization can result in inconsistent product quality, making it difficult to gain regulatory approvals and maintain patient trust. Inadequate quality control measures can lead to contamination, suboptimal cell quality, or the presence of potentially harmful impurities in stem cell products. Such issues pose serious safety concerns for patients who receive these therapies, undermining confidence in the industry. Regulatory agencies require stem cell manufacturers to adhere to strict quality control and manufacturing standards. Failure to meet these standards can lead to regulatory delays, fines, or product recalls, impeding market entry and growth. Stem cell manufacturing often involves complex processes, including cell isolation, expansion, differentiation, and quality testing. Ensuring consistency and reproducibility across these processes can be challenging, particularly as production scales up. Implementing robust quality control and standardization processes requires significant resources, including specialized equipment, highly trained personnel, and comprehensive testing protocols. This can be cost-prohibitive for smaller companies or startups, limiting their ability to enter the market. Stem cell research and manufacturing may involve collaboration between multiple research institutions and companies. Variability between laboratories and manufacturing facilities can lead to differences in product quality and hinder standardization efforts.

Key Market Trends

Advanced Bioprocessing Technologies

Advanced bioprocessing technologies enable the scalable production of stem cells and their derivatives. This is crucial for meeting the increasing demand for stem cell-based therapies, which often require large quantities of cells for clinical applications. Scalability reduces production costs and ensures a consistent supply of high-quality stem cell products. Automation, closed bioreactor systems, and advanced cell culture techniques streamline manufacturing processes and reduce labor and material costs. As a result, the cost of goods (COGs) for stem cell production decreases, making these therapies more financially viable for both manufacturers and patients. Advanced bioprocessing technologies help establish standardized and reproducible manufacturing processes. This standardization is essential for meeting regulatory requirements and ensuring product quality and consistency, which, in turn, enhances patient safety and confidence in stem cell therapies. Bioprocessing technologies include advanced monitoring and control systems that allow real-time monitoring of cell cultures. This enables early detection of deviations and potential issues, leading to better quality control and fewer batch failures. Closed bioreactor systems minimize the risk of contamination, ensuring that stem cell cultures remain sterile and uncontaminated throughout the manufacturing process. This is critical for maintaining product integrity and safety. Automation and optimized bioprocessing workflows reduce manufacturing timelines. Faster production cycles enable quicker access to stem cell-based therapies for patients, especially in urgent medical situations. For instance, in September 2021, LifeCell International Pvt. Ltd received an investment of INR 225 crore (USD 27.2 million) from OrbiMed Asia Partners IV in return for a minority stake, which was likely to enable the company to make a foray into adjacent new categories, such as fertility health and cell-based therapeutics.

Exosome-Based Therapies

Exosomes, small vesicles released by stem cells, contain a variety of bioactive molecules, including proteins, nucleic acids, and growth factors. These molecules have the potential to modulate immune responses, promote tissue regeneration, and regulate cellular functions. Exosome-based therapies can be applied to a wide range of medical conditions, including degenerative diseases, inflammatory disorders, and tissue injuries, expanding the market's scope and potential. Unlike traditional stem cell therapies, exosome-based therapies do not involve the transplantation of live cells. Instead, they utilize the therapeutic cargo contained within exosomes, which can reduce the regulatory and logistical complexities associated with cell-based therapies. This streamlined approach can expedite product development and market entry. Exosomes are less likely to trigger immune rejection or adverse immune responses compared to whole cells, making them a potentially safer option for patients. This characteristic can broaden the applicability of exosome-based therapies and attract a larger patient population. The manufacturing of exosome-based therapies is generally simpler and less resource-intensive than traditional cell-based approaches. This can lead to cost savings, making therapies more economically viable and accessible for patients. Exosome-based therapies can be more easily transported and distributed compared to cell-based products, as they do not require specialized storage or handling conditions. This facilitates their distribution on a global scale, increasing market reach. The development of exosome-based therapies has opened up new research and development opportunities within the stem cell manufacturing industry. Researchers are exploring methods to isolate, characterize, and engineer exosomes for specific therapeutic purposes, driving innovation in the sector.

Segmental Insights

Product Insights

Based on the Product, the Consumables segment is anticipated to witness substantial market growth throughout the forecast period. Consumables are fundamental to stem cell research, serving as the building blocks for experiments and studies. Researchers rely on consumables such as culture media, growth factors, and reagents to cultivate and manipulate stem cells in the laboratory. A robust supply of high-quality consumables is essential for advancing stem cell technologies and discovering new applications, driving continuous research and development efforts. The quality of consumables directly affects the reproducibility and consistency of stem cell manufacturing processes. Standardized and reliable consumables, such as culture media and reagents, ensure that stem cell cultures remain uncontaminated, grow efficiently, and meet quality control standards. This standardization is critical for regulatory compliance and ensuring product safety and efficacy. As the demand for stem cell-based therapies grows, the scalability of manufacturing processes becomes paramount. Consumables must be available in sufficient quantities to support large-scale production. Companies and research institutions require a stable supply chain of consumables to meet the scalability needs of the market. Consumables can constitute a significant portion of the overall production cost for stem cell-based therapies. Advances in the development and production of cost-effective consumables can lead to reduced manufacturing expenses, making stem cell therapies more economically viable and accessible for patients. Companies specializing in consumables for stem cell manufacturing continuously innovate to provide products that improve cell culture conditions, enhance cell viability, and support differentiation processes. These innovations contribute to the overall advancement of the stem cell manufacturing market by enabling better outcomes and expanded applications.

End User Insights

Based on the End User segment, the Pharmaceutical and Biotechnology Companies segment has been the dominant force in the market. Pharmaceutical and biotechnology companies often provide substantial financial resources for stem cell research and manufacturing. Their investments support the development of novel therapies and manufacturing technologies, driving innovation in the field. These companies have the infrastructure, expertise, and resources to conduct extensive research and development in the stem cell arena. Their efforts lead to the discovery of new applications, the improvement of existing technologies, and the development of proprietary stem cell-based therapies. Pharmaceutical and biotechnology firms are actively involved in the development of stem cell-based products, including therapies, drugs, and biologics. Their product pipelines contribute to the diversification and expansion of the stem cell manufacturing market. These companies have the capacity to design and conduct large-scale clinical trials, which are critical for demonstrating the safety and efficacy of stem cell-based therapies. Their involvement in clinical research accelerates the translation of stem cell treatments from the laboratory to the clinic. Pharmaceutical and biotechnology companies are well-versed in navigating complex regulatory pathways. Their regulatory expertise is invaluable for obtaining approvals and market authorizations for stem cell therapies, which can be a challenging process.

Download Free Sample Report

Regional Insights

North America, specifically the Stem Cell Manufacturing Market, dominated the market in 2022, primarily due to North America, particularly the United States, boasts a robust and well-funded research and development ecosystem for stem cell research. Leading universities, research institutions, and biotechnology companies in the region are at the forefront of stem cell innovation, driving the development of new manufacturing technologies and therapies. North America has established regulatory frameworks that, while rigorous, provide a clear path for the development and commercialization of stem cell-based therapies. Regulatory agencies like the U.S. Food and Drug Administration (FDA) have taken steps to create pathways for regenerative medicine products, facilitating market entry. The region is home to many prominent pharmaceutical and biotechnology companies with a keen interest in stem cell research and manufacturing. These companies invest heavily in stem cell-related initiatives, fuelling growth and innovation in the market. North America attracts significant financial investments in the stem cell manufacturing sector. Venture capital firms, government grants, and private investors contribute to the development of stem cell technologies and therapies, fostering market expansion. North America hosts a substantial number of stem cell experts, thought leaders, and key opinion leaders who contribute to the growth of the industry. Their expertise and influence play a crucial role in shaping research priorities and clinical practices. North America represents one of the largest pharmaceutical markets globally, which creates a significant demand for advanced therapies, including stem cell-based treatments. This demand drives investments in stem cell manufacturing and product development.

Recent Developments

• In August 2022, Applied StemCell, Inc. (ASC), a cell and gene therapy CRO/CDMO focused on supporting the research community and biotechnology industry for their needs in developing and manufacturing cell and gene products, expanded its Current Good Manufacturing (cGMP) facility. ASC has successfully carried out cell banking and product manufacturing projects in its current cGMP suite and is now set on building 4 additional cGMP cleanrooms, cryo-storage space, process development, and QC/QA space.
• In January 2022, stem cell manufacturing startup Cellino Biotech raised a USD 80 million Series A financing round led by Leaps by Bayer along with 8VC, Humboldt Fund, and new investors including Felicis Ventures and Khosla Ventures, that could fix a problem holding the biotech industry back. Cellino plans to expand access to stem cell-based therapies with the goal to build the first autonomous human cell foundry in 2025.
• In November 2022, ExCellThera Inc. completed the patient enrollment in its initial Phase 2 studies for high-risk leukemias and myelodysplastic syndromes (MDS). ECT-001 Cell Therapy, ExCellThera’s most advanced investigational drug, combines the proprietary molecule UM171 and an optimized culture system to produce unique UM171-expanded stem cell transplants, and it also enables the use of small cord blood units without compromising engraftment. The trials across the different phases show positive outcomes.

Key Market Players

• Thermo Fisher Scientific.
• Merck KGaA.
• AbbVie Inc.
• CO. LTD.
• Astellas Pharma Inc.
• Bristol-Myers Squibb Company.
• FUJIFILM Cellular Dynamics Inc.
• RHEACELL GmbH And Co. KG.
• Takeda Pharmaceutical Company Limited.
• Teva Pharmaceutical Industries Ltd.

Report Scope:

In this report, the Global Stem Cell Manufacturing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Stem Cell Manufacturing Market, By Product:

o   Consumables

o   Instruments

o   Stem Cell Lines

• Stem Cell Manufacturing Market, By Application:

o   Research Applications

o   Clinical Application

o   Cell and Tissue Banking Applications

• Stem Cell Manufacturing Market, By End User:

o   Pharmaceutical and Biotechnology Companies

o   Academic Institutes

o   Research Laboratories and Contract Research Organizations

o   Hospitals and Surgical Centers

o   Cell and Tissue banks

o   Others

• Stem Cell Manufacturing Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia-Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

§  Kuwait

§  Turkey

§  Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Stem Cell Manufacturing Market.

Available Customizations:

Global Stem Cell Manufacturing market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Stem Cell Manufacturing Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]